OGEN ORAGENICS INC

NYSE oragenics.com


$ 1.26 $ -0.04 (-3.08 %)    

Friday, 17-Oct-2025 11:34:19 EDT
QQQ $ 600.97 $ 3.35 (0.56 %)
DIA $ 460.38 $ 1.02 (0.22 %)
SPY $ 661.27 $ 1.79 (0.27 %)
TLT $ 91.11 $ -0.12 (-0.13 %)
GLD $ 386.75 $ -10.46 (-2.63 %)
$ 1.3
$ 1.29
$ 1.25 x 453
$ 1.28 x 2
$ 1.26 - $ 1.29
$ 1.01 - $ 18.90
44,022
na
5.37M
$ 1.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-14-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 04-17-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-03-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-04-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 02-16-2018 12-31-2017 10-K
32 10-31-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 02-27-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oragenics-selects-southern-star-research-as-clinical-research-organization-for-upcoming-phase-iia-clinical-trial-of-onp-002-lead-drug-candidate-for-concussion

Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological condit...

 oragenics-enters-manufacturing-agreement-with-sterling-pharma-for-gmp-production-of-concussion-drug-onp-002

Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today ann...

 oragenics-prices-public-offering-of-up-to-20m-of-preferred-stock-and-warrants

Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurologic...

 oragenics-receives-approval-from-hrec-in-australia-to-initiate-phase-ii-clinical-trial-evaluating-onp-002-for-treatment-of-mtbi

Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorde...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION